Metabolic syndrome rarely presents as a single, isolated disorder. Insulin resistance, visceral adiposity, dysglycaemia, hypertension and atherogenic dyslipidaemia frequently interact, increasing the risk of type 2 diabetes, cardiovascular disease, liver dysfunction, chronic kidney disease and other forms of end-organ injury.
Clinicians must be able to recognise this interconnected risk profile, interpret changing diagnostic criteria and develop management plans that address more than one metabolic abnormality at a time.
Clinical Guide to Metabolic Syndrome provides residents and clinicians with a structured clinical reference that connects the underlying pathophysiology of metabolic dysfunction with assessment, risk stratification and integrated management.
Beginning with the major definitions and diagnostic frameworks, the book explains how insulin resistance and dysfunctional adipose tissue contribute to glucose dysregulation, hypertension, abnormal lipid metabolism, systemic inflammation and progressive organ damage. Clinical findings are placed within a broader cardiometabolic framework, helping readers understand how individual abnormalities influence one another.
Inside this guide, readers will explore:
- ATP III, IDF, AHA/NHLBI and harmonised diagnostic criteria
- Molecular and tissue-specific mechanisms of insulin resistance
- Visceral adiposity, adipokine dysregulation and ectopic fat deposition
- Dysglycaemia, prediabetes and progression to type 2 diabetes
- Hypertension and antihypertensive selection in metabolic syndrome
- Atherogenic dyslipidaemia and interpretation of lipid profiles
- Metabolic-associated steatotic liver disease
- Cardiovascular and cardiorenal risk assessment
- Chronic kidney disease and pharmacological considerations
- PCOS, pregnancy, menopause and female-specific metabolic risk
- Obstructive sleep apnoea and sleep-related metabolic dysfunction
- Chronic inflammation, oxidative stress and prothrombotic mechanisms
- Genetic, epigenetic and familial contributions
- Nutrition, physical activity and behavioural-change strategies
- Metformin, GLP-1 receptor agonists, SGLT2 inhibitors, lipid-lowering therapies and integrated pharmacological management
- Diagnostic criteria comparisons and cardiometabolic risk tools
Written for residents and clinicians working across internal medicine, family medicine, endocrinology and cardiology, the book brings mechanistic science and clinical decision-making together in one organised resource.
Build a stronger understanding of metabolic syndrome as an interconnected clinical condition and approach cardiometabolic assessment and management with greater structure and confidence.
Add Clinical Guide to Metabolic Syndrome to your professional medical library today.
